TSLA has been sold off aggressively on strong Q2 delivery data (+24.9% YoY, 480,126 units), creating a classic 'sell-the-news' overreaction at $393.45 — near the pre-recovery-rally lows — that presents a compelling contrarian entry ahead of formal Q2 earnings. The stock has now given back the entirety of its 14.94% recovery rally, pricing in significant pessimism despite accelerating volume growth, while the macro backdrop of an impending Fed rate-cut cycle (triggered by the weak June jobs report) provides a tailwind for high-multiple growth stocks. At current levels, the risk/reward skews favorably toward a mean reversion into earnings with a defined stop below the recent lows.